Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,725,135

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $891.19 +0.12 (0.01%) 4:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Teva Migraine Candidate Succeeds in Second Phase III Study

Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.

    Novartis' (NVS) Tasigna Receives Label Update Nod in EU

    Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna's label.

      Novartis, Bristol-Myers Collaborate for Opdivo Combination

      Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.

        Seattle Genetics Reports Updated Results on Cancer Drug

        Seattle Genetics, Inc. (SGEN) and Astellas announced positive phase I results for pipeline candidate enfortumab vedotin (ASG-22ME).

          Novartis Presents Data on Tafinlar-Mekinist Combination

          Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

            Pfizer Provides Final Update on Phase II Talazoparib Study

            Pfizer Inc. (PFE) announced data from its phase II study, ABRAZO, which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1/2 positive (gBRCA+) mutations, showing anti-tumor activity

              Novartis Reports Positive Data on Breast Cancer Drug Kisqali

              Novartis AG (NVS) announced positive data from the phase III study, MONALEESA-2 on breast cancer drug Kisqali.

                Arpita Dutt headshot

                Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More

                Lilly (LLY) posted positive data on Cyramza while Teva's migraine drug delivered positive results in a late-stage study.

                  Eli Lilly's (LLY) Cancer Drug Cyramza Positive in Phase III

                  Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combination with docetaxel in patients with locally advanced or unresectable or metastatic urothelial carcinoma.

                    The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana

                    The Zacks Analyst Blog Highlights: Eli Lilly, HSBC, Marriott, American Airlines and Humana

                      Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

                      Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

                        Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                        After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                          Radius Health Osteoporosis Drug Positive in Phase III Study

                          Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.

                            AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk

                            AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.

                              Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers

                              Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .

                                Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion

                                Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.

                                  Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog

                                  Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).

                                    Arpita Dutt headshot

                                    Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More

                                    This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.

                                      Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

                                      We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

                                        5 Reasons Why Merck (MRK) is a Good Stock to Buy Now

                                        It looks like a great stock to buy now.

                                          Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

                                          Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.

                                            Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint

                                            Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies

                                              The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One

                                              The Zacks Analyst Blog Highlights: United Technologies, Lilly, American Express, Aetna, Las Vegas Sands and Capital One

                                                Arpita Dutt headshot

                                                Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

                                                Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.

                                                  Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved

                                                  Radius Health, Inc. (RDUS) posted a wider-than-expected loss of $1.32 per share in the first quarter of 2017 which were overshadowed by the approval of Tymlos.